Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics' proprietary CD8aß co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8
Investegate |https://immatics com/ Announcements | https://immatics com/: Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.